Overlap of differentially expressed genes (DEGs) and gene ontology (GO) analysis identifies two distinct gene expression patterns within <i>ATRX</i> aberrant neuroblastoma. by Michael R. van Gerven (16764526)

Characterization of neuroblastoma cell lines with ATRX multi-exon deletions. by Michael R. van Gerven (16764526)

Participant inclusion flowchart. by Shakila Meshkat (12360623)

“…In both unadjusted and adjusted models, participants with depressive symptoms had lower odds of FS (aOR = 0.347, 95% CI: 0.307,0.391, p<0.001). Moreover, in both unadjusted and adjusted models, for each 1-point increase in cognitive-affective (aOR = 0.850, 95% CI = 0.836,0.864, p <0.001) and somatic symptoms (aOR = 0.847, 95% CI = 0.831,0.863, p <0.001), odds of high FS decreased correspondingly. …”

Demographics of study sample. by Shakila Meshkat (12360623)

“…In both unadjusted and adjusted models, participants with depressive symptoms had lower odds of FS (aOR = 0.347, 95% CI: 0.307,0.391, p<0.001). Moreover, in both unadjusted and adjusted models, for each 1-point increase in cognitive-affective (aOR = 0.850, 95% CI = 0.836,0.864, p <0.001) and somatic symptoms (aOR = 0.847, 95% CI = 0.831,0.863, p <0.001), odds of high FS decreased correspondingly. …”

The technical route of the study. by Hongliang Zou (20707270)

“…<div><p>The study proposes a multi-sensor localization and real-timeble mapping method based on the fusion of 3D LiDAR point clouds and visual-inertial data, which addresses the issue of decreased localization accuracy and mapping in complex environments that affect the autonomous navigation of robot dogs. …”

Experimental results in the SubT-MRS dataset. by Hongliang Zou (20707270)

“…<div><p>The study proposes a multi-sensor localization and real-timeble mapping method based on the fusion of 3D LiDAR point clouds and visual-inertial data, which addresses the issue of decreased localization accuracy and mapping in complex environments that affect the autonomous navigation of robot dogs. …”

Antibodies used for western blotting and for immune fluorescence. by Michael R. van Gerven (16764526)

Sequences of sgRNAs used to make isogenic knock-out and ATRX MEDs. by Michael R. van Gerven (16764526)

All media and their components used for culturing the cell lines/organoids and isogenic clones. by Michael R. van Gerven (16764526)

Gene set enrichment analysis (GSEA) reveals two opposing expression patterns within <i>ATRX</i> aberrant neuroblastoma related to ribosome biogenesis. by Michael R. van Gerven (16764526)

Primers used for cloning homology arm plasmids and PiggyBac doxycycline inducible <i>ATRX</i> wild-type plasmid. by Michael R. van Gerven (16764526)

The number of significantly downregulated and upregulated differentially expressed genes for all 8 analyses with an p-adjusted value of 0.05. by Michael R. van Gerven (16764526)

DataSheet7_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”

DataSheet6_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”

DataSheet4_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”

DataSheet5_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”

DataSheet1_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.PDF by Sabrina R. Mackinnon (12496324)

“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”

DataSheet3_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”

DataSheet2_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

“…<p>Primary hyperoxaluria type I (PH1) is caused by AGXT gene mutations that decrease the functional activity of alanine:glyoxylate aminotransferase. …”

Genetic overview of (un)successful clones validated by Sanger sequencing on both genomic DNA and RNA (cDNA). by Michael R. van Gerven (16764526)